Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avalon Globocare (AVCO)

Avalon Globocare (AVCO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,593
  • Shares Outstanding, K 78,985
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -18,070 K
  • 60-Month Beta 0.92
  • Price/Sales 92.47
  • Price/Cash Flow N/A
  • Price/Book 37.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/19/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5200 +17.11%
on 05/15/20
2.1935 -18.85%
on 05/08/20
+0.0600 (+3.49%)
since 04/22/20
3-Month
0.5000 +256.00%
on 03/12/20
2.1935 -18.85%
on 05/08/20
+0.1600 (+9.88%)
since 02/21/20
52-Week
0.5000 +256.00%
on 03/12/20
2.8000 -36.43%
on 06/28/19
-0.5900 (-24.89%)
since 05/22/19

Most Recent Stories

More News
Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR(TM) Technology for Blood Cancers

-- Capable of Targeting Multiple Tumor Antigens for Potentially Superior Therapeutic Effects

AVCO : 1.7800 (-1.66%)
Orbia Announces First Quarter 2020 Financial Results

Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA) ("the Company" or "Orbia") today released unaudited results for the first quarter of 2020.

AVCO : 1.7800 (-1.66%)
Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX(TM) Product Development and Commercialization

-- Signed Three-Way Material Transfer Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine

AVCO : 1.7800 (-1.66%)
Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality

-- Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as "Molecular Mop" to Remove Excessive Cytokines ("Cytokine Storm") Related to Coronavirus Infection and Cellular Immunotherapy...

AVCO : 1.7800 (-1.66%)
Orbia Announces Conference Call for Its First Quarter 2020 Earnings Results

Orbia Advance Corporation, S.A.B. de C.V. will release its first quarter 2020 earnings results after the market closes on Wednesday, April 29th, 2020.

AVCO : 1.7800 (-1.66%)
Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline

--Headcount reduction of 340 - approximately 53 percent of workforce

AVCO : 1.7800 (-1.66%)
SAGE : 38.94 (+2.53%)
Orbia Announces Fourth Quarter and Full Year Financial Results for 2019

Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) ("the Company" or "Orbia") today released unaudited results for the fourth quarter and full year of 2019. Despite headwinds in some of Orbia's key...

AVCO : 1.7800 (-1.66%)
Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020

Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it will present at the 32 Annual ROTH Conference being held on...

AVCO : 1.7800 (-1.66%)
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the "Cellular Therapy in the Asia Pacific Region" Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASTCT and CIBMTR Tandem Meeting 2020

Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D.,...

AVCO : 1.7800 (-1.66%)
Orbia Announces Conference Call for Its Fourth Quarter and Full Year 2019 Financial Results

Orbia Advance Corporation, S.A.B. de C.V. will release its fourth quarter and full year 2019 earnings results after the market closes on Wednesday, February 26th, 2020.

AVCO : 1.7800 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade AVCO with:

Business Summary

Avalon GloboCare Corp. outsourced healthcare services. It serves healthcare institutions, individual patients, academia and corporations sector. The company provides healthcare management which comprises cell-based technologies and therapeutics, genomic diagnostics and precision medicine, international...

See More

Key Turning Points

2nd Resistance Point 1.9000
1st Resistance Point 1.8400
Last Price 1.7800
1st Support Level 1.7100
2nd Support Level 1.6400

See More

52-Week High 2.8000
Fibonacci 61.8% 1.9214
Last Price 1.7800
Fibonacci 50% 1.6500
Fibonacci 38.2% 1.3786
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar